



The ACME Laboratories Ltd.

MANUFACTURERS OF ETHICAL DRUGS & MEDICINES

ISO 9001:2015 CERTIFIED COMPANY

Office Copy

Ref. No. ACME/CA/CS/2025/019

04 February 2025

The Chief Regulatory Officer

Dhaka Stock Exchange PLC

DSE Tower, House-46, Road-21, Nikunja-2,

Dhaka-1229.

Subject: Report on Shareholding of the sponsors/directors, foreigners, institutions and shareholders who hold 5% or more of listed securities of The ACME Laboratories Ltd.

Dear Sir,

Pursuant to the regulation 35 (2) of the Dhaka Stock Exchange (Listing) Regulations, 2015 we are pleased to enclose herewith the statement of shareholding position of The ACME Laboratories Ltd. as on 31 January 2025 as per prescribed format of DSE and CSE.

Thanking you.

With best regards,

Kazi Mohammed Badruddin, FCA, FCMA
Executive Director & CFO

Masudur Rahman Bhuiyan, FCS
Company Secretary

Enclosure: As stated above.



Corporate Office :

Court de la **ACME**

1/4, Kallayanpur, Mirpur Road
Dhaka-1207, Bangladesh.

Phone : +88-02-8091051-3

Fax : +88-02-58056299

E-mail : headoffice@acmeglobal.com

www.acmeglobal.com

Plant:

Dharmrai, Dhaka, Bangladesh.

Phone : +88-02-7730881-2

+88-02-7730816-7, 7730142

Fax : +88-02-7730141

E-mail : plant@acmeglobal.com

1) Name of the Issuer : The ACME Laboratories Ltd.

2) Applicable Month : 31-01-2025

3) Total Paid-up Capital (Tk.): 2,116,017,000.00

4) No. of total paid-up securities: 211,601,700

5) % of Paid - up Capital held by:

A. Sponsors/Promoters and Directors: 42.42%

B. Govt.: 0.00%

C. Institute: 29.42%

D. Foreign: 0.13%

E. Public: 28.03%

6) Details of shareholding / sponsors / directors:

Sl. No.	Name	Status (Sponsor/ Promoter/ Director / Sponsor Director / Nominated Director / Independent Director / Depositor Director etc.)	No. of securities held as on 31.01.2025		% of total no. of paid-up securities as on 31.01.2025		No. of securities increased / (decreased) during reported period (A) - (B)	Reason for changes
			Reporting month 31.01.2025 (A)	Previous month 31.12.2024 (B)	Reporting month 31.01.2025	Previous month 31.12.2024		
01	Mrs. Nagina Afzal Sinha	Chairman	11,888,433	11,888,433	5.62%	5.62%	N/A	N/A
02	Mr. Mizanur Rahman Sinha	Sponsor / Managing Director	8,574,000	8,574,000	4.05%	4.05%	N/A	N/A
03	Dr. Jabilur Rahman Sinha	Deputy Managing Director	4,860,696	4,860,696	2.30%	2.30%	N/A	N/A
04	Mrs. Jahanara Mizan Sinha	Sponsor / Deputy Managing Director	5,290,000	5,290,000	2.50%	2.50%	N/A	N/A
05	Ms. Tasneem Sinha	Deputy Managing Director	9,761,300	9,761,300	4.61%	4.61%	N/A	N/A
06	Mr. Tanveer Sinha	Director	9,600,659	9,600,659	4.54%	4.54%	N/A	N/A
07	Mrs. Sabrina Juned	Director	9,102,613	9,102,613	4.30%	4.30%	N/A	N/A
08	Mr. Fahim Sinha	Director	9,375,961	9,375,961	4.43%	4.43%	N/A	N/A
09	Mrs. Parveen Akhter Khanam	Sponsor Shareholder	5,319,158	5,319,158	2.51%	2.51%	N/A	N/A
10	Mrs. Khurshid Jehan Dabir	Sponsor Shareholder	725	725	0.00%	0.00%	N/A	N/A
11	Mr. Md. Abul Hossain	Nominee Director of Investment Corporation of Bangladesh (ICB)	15,993,484	15,993,484	7.56%	7.56%	N/A	N/A
12	Mr. Das Deba Prashad	Independent Director	-	-	0.00%	0.00%	N/A	N/A
13	Mr. Ehsan Ul Fattah	Independent Director	-	-	0.00%	0.00%	N/A	N/A
14	Mr. Kazi Sanaul Hoq	Independent Director	-	-	0.00%	0.00%	N/A	N/A
Total			89,767,029	89,767,029	42.42%	42.42%	N/A	N/A

7) Details of shareholding of foreigner, institution and shareholder who holds 5% or more securities outstanding other than sponsors / directors:

Sl. No.	Name of foreigner, institution and shareholder who holds 5% or more other than sponsors / directors	No. of securities held as on 31.01.2025		% of total no. of paid-up securities as on 31.01.2025		No. of securities increased / (decreased) during reported period (A) - (B)	Reason for changes
		Reporting month 31.01.2025 (A)	Previous month 31.12.2024 (B)	Reporting month 31.01.2025	Previous month 31.12.2024		
01	ICB Unit Fund	11,827,482	11,788,280	5.59%	5.57%	39,202	Purchased
Total		11,827,482	11,788,280	5.59%	5.57%	39,202	Purchased

Kazi Mohammed Badruddin, FCA, FCMA
Executive Director & CFO

Masudur Rahman Bhuiyan, FCS
Company Secretary

Annexure-4 of Schedule B